Non-microbial approach for Helicobacter pylori as faster track to prevent gastric cancer than simple eradication

World J Gastroenterol. 2013 Dec 21;19(47):8986-95. doi: 10.3748/wjg.v19.i47.8986.


Although the International Agency for Research on Cancer declared Helicobacter pylori (H. pylori) as a definite human carcinogen in 1994, the Japanese Society for Helicobacter Research only recently (February 2013) adopted the position that H. pylori infection should be considered as an indication for either amelioration of chronic gastritis or for decreasing gastric cancer mortality. Japanese researchers have found that H. pylori eradication halts progressive mucosal damage and that successful eradication in patients with non-atrophic gastritis most likely prevents subsequent development of gastric cancer. However, those who have already developed atrophic gastritis/gastric atrophy retain potential risk factors for gastric cancer. Because chronic perpetuated progression of H. pylori-associated gastric inflammation is associated with increased morbidity culminating in gastric carcinogenesis, a non-microbial approach to treatment that provides long-term control of gastric inflammation through nutrients and other interventions may be an effective way to decrease this morbidity. This non-microbial approach might represent a new form of prerequisite "rescue" therapy that provides a quicker path to the prevention of gastric cancer as compared to simple eradication.

Keywords: Atrophic gastritis; Gastric cancer; Helicobacter pylori; Non-microbial approach; Prevention.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Anticarcinogenic Agents / therapeutic use*
  • Antioxidants / therapeutic use
  • Fatty Acids, Omega-3 / therapeutic use
  • Gastritis, Atrophic / microbiology
  • Gastritis, Atrophic / therapy*
  • Gastrointestinal Agents / therapeutic use*
  • Helicobacter Infections / complications
  • Helicobacter Infections / microbiology
  • Helicobacter Infections / therapy*
  • Helicobacter pylori / pathogenicity*
  • Humans
  • Phytochemicals / therapeutic use
  • Probiotics / therapeutic use*
  • Risk Factors
  • Stomach Neoplasms / microbiology
  • Stomach Neoplasms / prevention & control*
  • Treatment Outcome


  • Anti-Inflammatory Agents
  • Anticarcinogenic Agents
  • Antioxidants
  • Fatty Acids, Omega-3
  • Gastrointestinal Agents
  • Phytochemicals